Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28817801 | 0.85 | PLA2G1B (0.42) | PLA2G1BPLA2G2ASIGMAR1MEN1POLB | |
| SCHEMBL7379244 | 0.78 | PLA2G1B (0.43) | PLA2G1BPLA2G2ASIGMAR1MEN1POLB | |
| SCHEMBL4663456 | 0.76 | SIGMAR1 (0.34) | PLA2G1BPLA2G2ASIGMAR1MEN1POLB | |
| SCHEMBL20284332 | 0.76 | OPRM1 (0.42) | PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL3715809 | 0.76 | OPRM1 (0.42) | PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL5494737 | 0.74 | PLA2G1B (0.40) | PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL4078267 | 0.74 | PLA2G1B (0.61) | PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL6391075 | 0.74 | SIGMAR1 (0.33) | PLA2G1BPLA2G2ASIGMAR1MEN1POLB | |
| SCHEMBL4908461 | 0.74 | PLA2G1B (0.40) | PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL6519105 | 0.73 | MEN1 (0.39) | PLA2G1BPLA2G2ASIGMAR1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335078-A | Exon skipping of FC-epsilon-RI-beta and MS4A6A in combination for the treatment of allergic diseases | 北卡罗来纳州立大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-107667174-B | Antisense oligonucleotides for treating dystrophic epidermolysis bullosa | 翼治疗有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-107567498-B | Oligonucleotides pairing with COL7a1 exon 73 for the treatment of epidermolysis bullosa | 翼治疗有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-107406852-B | Oligonucleotide therapy for leber's congenital amaurosis | ProQR治疗上市公司Ⅱ | 2021-06-11 | — | — | CN | disclosed |
| CN-110997916-A | Antisense oligonucleotides for treating Stargardt's disease | ProQR治疗上市公司Ⅱ | 2020-04-10 | — | — | CN | disclosed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | disclosed |